Source: Eur Respir J, 56 (6) 2003967; 10.1183/13993003.03967-2020
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Kevin K. Brown, Rozsa Schlenker-Herceg, Athol U. Wells. Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”. Eur Respir J, 56 (6) 2003967; 10.1183/13993003.03967-2020

Member's Comments

No comment yet.

Related content which might interest you: Comment on “The natural history of progressive fibrosing interstitial lung diseases” Source: Eur Respir J, 56 (6) 2003508; 10.1183/13993003.03508-2020 Year: 2020 The natural history of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 55 (6) 2000085; 10.1183/13993003.00085-2020 Year: 2020 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Prevalence of progressive fibrosing interstitial lung disease Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs) Year: 2018 Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Source: Eur Respir Rev 2012 21: 355-361 Year: 2012 Genetic susceptibilty and manifestation of progressive fibrosing interstitial lung diseases. Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis Year: 2020 Clinicoradiological features of chronic fibrosing interstitial pneumonia with smoking history Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 Smoking-related interstitial lung diseases: a concise review Source: Eur Respir J 2001; 17: 122-132 Year: 2001 Relevance of the expert ILD clinical-radiological evaluation of referred cases to the MDT Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Source: Eur Respir J 2011; 38: 384-391 Year: 2011 Genetics of fibrosing lung diseases Source: Eur Respir J 2005; 25: 915-927 Year: 2005 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases Source: Eur Respir J, 54 (3) 1900161; 10.1183/13993003.00161-2019 Year: 2019 Interstitial lung diseases: course report Source: Breathe, 14 (3) 184; 10.1183/20734735.019718 Year: 2018 Interstitial lung diseases: course report Source: Breathe, 15 (4) 270; 10.1183/20734735.0259-2019 Year: 2019 Chronic hypersensitivity pneumonitis with familial history of interstitial lung disease Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Interstitial lung diseases: course report Source: Breathe 2016; 12: 213-215 Year: 2016 How should we approach the treatment of progressive fibrosing ILDs? Source: International Congress 2019 – New Horizons in The Treatment of Pulmonary Fibrosis Year: 2019 Rare interstitial lung diseases of environmental origin Source: Eur Respir Mon 2011; 54: 301-316 Year: 2011 Genetics variants in familial interstitial pneumonia and progressive fibrosing interstitial lung disease (PF-ILD) Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis Year: 2021